Iovance Biotherapeutics, Inc. IOVA Inventory write-downs
Inventory write-downs at other companies
Other financials
Where this comes from
Reported directly by Iovance Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InventoryWriteDown.
The official record: Iovance Biotherapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Iovance Biotherapeutics, Inc.'s inventory write-downs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Iovance Biotherapeutics, Inc.'s inventory write-downs?
- Iovance Biotherapeutics, Inc. (IOVA) reported inventory write-downs of -$506K in Q1 2026.
- How has Iovance Biotherapeutics, Inc.'s inventory write-downs changed year-over-year?
- Iovance Biotherapeutics, Inc.'s inventory write-downs decreased by 8333.3% year-over-year, from -$6K to -$506K.
- What does inventory write-downs mean?
- Reflects the reduction in the carrying value of inventory when its market value falls below its cost due to obsolescence, spoilage, or damage. For a biopharmaceutical company, this often relates to clinical trial materials or commercial product batches that no longer meet quality or regulatory standards. High levels may indicate inefficiencies in supply chain management or product development.